NSCLC

Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for October 26, 2021 CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS…

Read More »